tradingkey.logo

Redhill Biopharma Ltd

RDHL

1.690USD

-0.010-0.59%
收盘 09/19, 16:00美东报价延迟15分钟
5.63M总市值
0.49市盈率 TTM

Redhill Biopharma Ltd

1.690

-0.010-0.59%
关于 Redhill Biopharma Ltd 公司
RedHill Biopharma Ltd 是一家总部位于以色列的专业生物制药公司,主要专注于胃肠道和传染病。RedHill 推广的胃肠道药物包括用于治疗幽门螺杆菌 (H. pylori) 感染的 Talicia 和用于治疗旅行者腹泻的 Aemcolo。RedHill 的临床后期开发项目包括::info: RHB-204,用于治疗肺部非结核分枝杆菌 (NTM) 疾病;opaganib (ABC294640),针对多种适应症的宿主靶向 SPHK2 抑制剂,RHB-107 (upamostat),一种具有大流行防备潜力的口服宿主靶向丝氨酸蛋白酶抑制剂,正处于后期开发阶段,用于治疗非住院症状性 COVID-19,并针对多种其他癌症和炎症性胃肠道疾病;RHB-104 用于克罗恩病;以及 RHB-102,用于治疗化疗和放疗引起的恶心和呕吐。
公司简介
公司代码RDHL
公司名称Redhill Biopharma Ltd
上市日期Feb 01, 2011
CEOMr. Dror Ben-Asher
员工数量35
证券类型Depository Receipt
年结日Feb 01
公司地址21 Ha'arba'a St.
城市TEL AVIV-YAFO
上市交易所NASDAQ Capital Market Consolidated
国家Israel
邮编6473921
电话97235413131
网址https://www.redhillbio.com/
公司代码RDHL
上市日期Feb 01, 2011
CEOMr. Dror Ben-Asher
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Shmuel Cabilly, Ph.D.
Dr. Shmuel Cabilly, Ph.D.
Independent Director
Independent Director
--
--
Ms. Patricia Anderson
Ms. Patricia Anderson
Senior Vice President - Regulatory Affairs
Senior Vice President - Regulatory Affairs
--
--
Mr. Razi Ingber
Mr. Razi Ingber
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Alexandra Okmian
Mr. Alexandra Okmian
Investor Relations
Investor Relations
--
--
Mr. Adi Frish
Mr. Adi Frish
Chief Corporate and Business Development Officer
Chief Corporate and Business Development Officer
--
--
Mr. Dror Ben-Asher
Mr. Dror Ben-Asher
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Dr. Reza Fathi, Ph.D.
Dr. Reza Fathi, Ph.D.
Senior Vice President - Research and Development
Senior Vice President - Research and Development
--
--
Mr. Ofer Tsimchi
Mr. Ofer Tsimchi
Independent Director
Independent Director
--
--
Dr. Kenneth Reed, M.D.
Dr. Kenneth Reed, M.D.
Independent Director
Independent Director
--
--
Mr. Guy Goldberg, J.D.
Mr. Guy Goldberg, J.D.
Chief Business Officer
Chief Business Officer
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Shmuel Cabilly, Ph.D.
Dr. Shmuel Cabilly, Ph.D.
Independent Director
Independent Director
--
--
Ms. Patricia Anderson
Ms. Patricia Anderson
Senior Vice President - Regulatory Affairs
Senior Vice President - Regulatory Affairs
--
--
Mr. Razi Ingber
Mr. Razi Ingber
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Alexandra Okmian
Mr. Alexandra Okmian
Investor Relations
Investor Relations
--
--
Mr. Adi Frish
Mr. Adi Frish
Chief Corporate and Business Development Officer
Chief Corporate and Business Development Officer
--
--
Mr. Dror Ben-Asher
Mr. Dror Ben-Asher
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 9月6日 周六
更新时间: 9月6日 周六
持股股东
股东类型
持股股东
持股股东
占比
Heights Capital Management, Inc.
2.10%
UBS Financial Services, Inc.
0.24%
Desjardins Securities Inc.
0.10%
GAMMA Investing LLC
0.06%
SBI Securities Co., Ltd.
0.06%
其他
97.43%
持股股东
持股股东
占比
Heights Capital Management, Inc.
2.10%
UBS Financial Services, Inc.
0.24%
Desjardins Securities Inc.
0.10%
GAMMA Investing LLC
0.06%
SBI Securities Co., Ltd.
0.06%
其他
97.43%
股东类型
持股股东
占比
Investment Advisor
2.51%
Research Firm
0.32%
Investment Advisor/Hedge Fund
0.09%
其他
97.07%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
39
100.72K
4.39%
-24.30K
2025Q1
45
100.27K
5.67%
-27.27K
2024Q4
61
86.70K
6.77%
-35.73K
2024Q3
77
75.64K
5.91%
-52.57K
2024Q2
82
147.72K
11.56%
-10.64K
2024Q1
84
175.94K
13.78%
+109.25K
2023Q4
94
19.30K
14.67%
-65.78K
2023Q3
106
74.17K
44.30%
+53.53K
2023Q2
113
26.79K
29.96%
+840.00
2023Q1
122
24.63K
29.02%
+7.31K
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Heights Capital Management, Inc.
70.00K
3.05%
+70.00K
--
Jan 25, 2024
UBS Financial Services, Inc.
2.00
0%
-4.36K
-99.95%
Mar 31, 2025
Desjardins Securities Inc.
3.39K
0.15%
--
--
Mar 31, 2025
GAMMA Investing LLC
3.57K
0.16%
-1.52K
-29.89%
Mar 31, 2025
SBI Securities Co., Ltd.
5.00
0%
+3.00
+150.00%
Mar 31, 2025
Morgan Stanley & Co. LLC
11.00
0%
-2.20K
-99.50%
Mar 31, 2025
Rhumbline Advisers Ltd. Partnership
1.39K
0.06%
+190.00
+15.86%
Mar 31, 2025
BofA Global Research (US)
303.00
0.01%
+301.00
+15050.00%
Mar 31, 2025
Yorkville Asset Management, Inc.
14.00
0%
--
--
Sep 30, 2024
查看更多
持股ETF
机构名称
占比
暂无数据
分红派息
近5年累计派现 0.00 美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
Aug 06, 2024
Merger
25→1
Aug 06, 2024
Merger
25→1
Aug 06, 2024
Merger
25→1
Aug 06, 2024
Merger
25→1
Mar 17, 2023
Merger
40→1
Mar 17, 2023
Merger
40→1
公告日期
类型
比率
Aug 06, 2024
Merger
25→1
Aug 06, 2024
Merger
25→1
Aug 06, 2024
Merger
25→1
Aug 06, 2024
Merger
25→1
Mar 17, 2023
Merger
40→1
Mar 17, 2023
Merger
40→1
Mar 17, 2023
Merger
40→1
Mar 17, 2023
Merger
40→1
KeyAI